研究者詳細 - 瀧澤　淳

論文 - 瀧澤　淳

分割表示 121 件中 61 - 80 件目／全件表示 >>

Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single timepoint for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation. 査読

Furukawa T, Kurasaki-Ida T, Masuko M, Tsukada N, Okazuka K, Sato N, Yano T, Abe T, Momoi A, Shibasaki Y, Higashimura M, Karimata K, Moriyama M, Kuroha T, Takizawa J, Toba K, Narita M, Fuse I, Takahashi M, Aizawa Y

Int J Hematol. 92 ( 1 ) 144 - 151 2010年7月

Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system - Laboratory investigation 査読

Jie Li, Hiroaki Okamoto, Chunyue Yin, Jay Jagannathan, Jun Takizawa, Sadao Aoki, Sven Glaesker, Elisabeth J. Rushing, Alexander O. Vortmeyer, Edward H. Oldfield, Ryuya Yamanaka, Zhengping Zhuang

JOURNAL OF NEUROSURGERY 109 ( 3 ) 536 - 546 2008年9月

Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma 査読

Anri Saitoh, Miwako Narita, Norihiro Watanabe, Nozomi Tochiki, Noriyuki Satoh, Jun Takizawa, Tatsuo Furukawa, Ken Toba, Yoshifusa Aizawa, Shohji Shinada, Masuhiro Takahashi

MEDICAL ONCOLOGY 25 ( 2 ) 137 - 147 2008年6月

Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation 査読

Jun Takizawa, Sadao Aoki, Tori Kurasaki, Masutaka Higashimura, Keiichiro Honma, Toshiki Kitajima, Akihito Momoi, Hidenobu Takahashi, Naoya Nakamura, Tatsuo Furukawa, Yoshifusa Aizawal

AMERICAN JOURNAL OF HEMATOLOGY 82 ( 12 ) 1113 - 1115 2007年12月

Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. 査読

Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M

J Clin Exp Hematop. 47 ( 2 ) 61 - 72 2007年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：The Japanese Society for Lymphoreticular Tissue Research

In order to establish the method of generating powerful γδ T cells for anti-tumor immunotherapy, we investigated the effects of monocyte-derived dendritic cells (mo-DCs) on anti-tumor cytotoxicity of expanded γδ T cells. Activation of γδ T cells co-cultured for 2-3 days with immature or mature mo-DCs was evaluated by CD69 expression and anti-tumor cytotoxicity using two assays : the 5- (and 6-) carboxyfluorescein diacetate, succinimidyl ester-based cytotoxicity assay and the calcein-AM-based Terascan assay. γδ T cells were used as effector cells and myeloma cell line (RPMI8226) or chronic myelogenous leukemia blastic crisis cell line (C2F8) were used as target cells. CD69 expression on γδ T cells was enhanced by co-culture with both immature and mature mo-DCs in a cell-number-dependent fashion. CD69 expression was enhanced after addition of mo-DCs of either autologous or allogeneic origin. Activation of γδ T cells with mo-DCs enhanced anti-tumor cytotoxicity of γδ T cells against RPMI8226 and C2F8 in an effector-to-target ratio-dependent manner. Activation of γδ T cells by mo-DCs was associated with the enhancement of anti-tumor cytotoxicity of γδ T cells. Potent γδ T cells activated by mo-DCs were considered to be applicable to an efficient γδ T cell-mediated immunotherapy for tumors. [J Clin Exp Hematopathol 47(2) : 61-72, 2007]

DOI： 10.3960/jslrt.47.61

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2008186007

Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients 査読

Hidenobu Takahashi, Tatsuo Furukawa, Toshio Yano, Naoko Sato, Jun Takizawa, Tori Kurasaki, Takashi Abe, Miwako Narita, Masayoshi Masuko, Satoru Koyama, Ken Toba, Masuhiro Takahashi, Yoshifusa Aizawa

EXPERIMENTAL HEMATOLOGY 35 ( 7 ) 1091 - 1099 2007年7月

Plasma brain natriuretic peptide during myeloablative stem cell transplantation. 査読

Masuko M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K, Aoki S, Fuse I, Kodama M, Furukawa T, Aizawa Y

Internal medicine (Tokyo, Japan) 46 ( 9 ) 551 - 555 2007年

記述言語：英語出版者・発行元：The Japanese Society of Internal Medicine

Objective: Cardiovascular complication is one of the serious complications in stem cell transplantation (SCT). We measured plasma brain natriuretic peptide (BNP) concentrations in patients who received SCT to evaluate possible cardiac toxicity of the regimens employed in SCT. Patients: Ten patients with allogeneic SCT and 5 patients with autologous SCT using myeloablative conditioning regimens were enrolled. The preparative chemotherapy for 8 patients with allogeneic SCT included cyclophosphamide (60 mg/kg i.v. for 2 days) and other drugs and that for autologous SCT included cyclophosphamide (50 mg/kg for 2 days) and other drugs. Total body irradiation (TBI) was employed only in the patients who received allogeneic SCT. Method: Plasma BNP was measured using a radioimmunoassay for human BNP before and after SCT. Results: In 13 of 15 patients, BNP levels were elevated after SCT. In patients who received a total body irradiation (TBI) of 13.2 Gy, BNP levels were higher than those without irradiation (p=0.01). The BNP level reached a peak within 6 months after SCT in most patients and fell thereafter. But 7 of the 15 patients (46.7%) had an abnormally high level of plasma BNP even after 6 months of SCT which suggests subclinical myocardial damage. Conclusion: A rise in plasma BNP was frequently observed after SCT, and may be considered to represent cardiac damage caused by the preparative chemotherapy and/or total body irradiation. Since a rise was noted 6 months after SCT, long-term evaluation of cardiac function is important.

DOI： 10.2169/internalmedicine.46.6188

PubMed

CiNii Article

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2007315596

Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody 査読

N Nakamura, H Hase, D Sakurai, S Yoshida, M Abe, N Tsukada, J Takizawa, S Aoki, M Kojima, S Nakamura, T Kobata

VIRCHOWS ARCHIV 447 ( 1 ) 53 - 60 2005年7月

IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy 査読

G Hatzivassiliou, Miller, I, J Takizawa, N Palanisamy, PH Rao, S Iida, S Tagawa, M Taniwaki, J Russo, A Neri, G Cattoretti, R Clynes, C Mendelsohn, RSK Chaganti, R Dalla-Favera

IMMUNITY 14 ( 3 ) 277 - 289 2001年3月

5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: A case report 査読

Hidenobu Takahashi, Tatsuo Furukawa, Shigeo Hashimoto, Naoko Kanazawa, Naoaki Satoh, Noriatsu Suzuki, Jun Takizawa, Yumiko Uesugi, Masuhiro Takahashi, Yoshifusa Aizawa, Tadashi Koike

American Journal of Hematology 64 ( 2 ) 120 - 123 2000年

The TCL1 oncogene is not overexpressed in patients with adult T cell leukemia 査読

J Takizawa, M Seto

LEUKEMIA 13 ( 2 ) 314 - 314 1999年2月

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia 査読

J Takizawa, R Suzuki, H Kuroda, A Utsunomiya, Y Kagami, T Joh, Y Aizawa, R Ueda, M Seto

JAPANESE JOURNAL OF CANCER RESEARCH 89 ( 7 ) 712 - 718 1998年7月

Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation 査読

Tatsuroh Joh, Yoshitoyo Kagami, Kazuhito Yamamoto, Tatsuya Segawa, Jun Takizawa, Toshitada Takahashi, Ryuzo Ueda, Masao Seto

Oncogene 13 ( 9 ) 1945 - 1953 1996年

Fanconi貧血と思われる再生不良性貧血に続発した急性骨髄性白血病に親子間同種骨髄移植を施行した1症例査読

瀧澤淳, 岸賢治, 森山美昭, 橋本誠雄, 後藤隆夫, 樋口渉, 和田研, 成田美和子, 青木定夫, 高橋益広, 小池正, 柴田昭

臨床血液 36 ( 6 ) 615 - 620 1995年6月

担当区分：筆頭著者記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本血液学会

症例は19歳，男性。生後1カ月より貧血を指摘され，低身長，右母指形成不全，皮膚色素沈着，精神発達遅延など多発奇形を合併しており，Fanconi貧血(FA)が疑われ経過観察されてきた。1993年1月より，汎血球減少が著明となり，頻回の輸血が必要となったため，8月31日当科入院となった。入院時骨髄穿刺では，骨髄は有核細胞数1.1×104/μlと低形成であったが，芽球42.0%, 前骨髄球9.6%を認め，AML (M2)へ移行したものと判断した。少量Ara-C療法で寛解は得られず，HLA完全一致，MLC陰性の父親をdonorとして，10月15日同種骨髄移植を施行した。移植前処置はcyclophosphamideを用いず，Ara-Cとetoposideの大量投与とTBI (12Gy)を併用したが，重篤なregimen related toxicityは認めず，骨髄生着が得られた。急性GVHD予防はciclosporin Aとmethotrexateを用い，GVHDは認められなかった。白血病に移行したFAに対するBMT成功例は少なく，文献的考察を含め報告する。

DOI： 10.11406/rinketsu.36.615

CiNii Article

CiNii Books

researchmap

Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Yuri Furuyama, Tatsuya Suwabe, Ayako Kawakami, Hodaka Yonezawa, Takayuki Katagiri, Kyoko Fuse, Yasuhiko Shibasaki, Takashi Ushiki, Jun Takizawa, Hirohito Sone, Masayoshi Masuko

Cureus 2025年7月

NelarabineとMTX髄注による脊髄後索障害を認めたETP-ALLの1例

藤野千秋, 片桐隆幸, 武田ルイ, 川上絢子, 米沢穂高, 諏訪部達也, 柴崎康彦, 布施香子, 瀧澤淳, 曽根博仁, 増子正義, 山岸拓磨

臨床血液 66 ( 5 ) 381 - 381 2025年5月

Evans症候群を合併したNodal T follicular helper cell lymphoma NOS(nTFHL-NOS)の一例

福田正穂, 片桐隆幸, 藤野千秋, 川上絢子, 水戸部正樹, 土田拓睦, 米沢穂高, 諏訪部達也, 布施香子, 柴崎康彦, 増子正義, 曽根博仁, 三好寛明, 大島孝一, 瀧澤淳

日本リンパ腫学会会誌 65 127 - 127 2025年5月

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. 国際誌

Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata, Yasuo Ejima, Dai Maruyama, Nobuko Kubota, Takeshi Maeda, Jun Takizawa, Nobuhiro Hiramoto, Masahiro Takeuchi, Rika Sakai, Noriko Fukuhara, Senzo Taguchi, Naoko Asano, Motoko Yamaguchi, Ritsuro Suzuki

Leukemia 39 ( 4 ) 909 - 916 2025年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19-90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014-2017 vs. 50.7% for 2018-2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.

DOI： 10.1038/s41375-025-02527-4

PubMed

researchmap

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. 国際誌

Kazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Akinao Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Akiko Meguro, Yoshihiro Kin, Yosuke Minami, Daigo Hashimoto, Takahiro Nishiyama, Satoko Shimada, Yasufumi Masaki, Masataka Okamoto, Yoshiko Atsuta, Hitoshi Kiyoi, Ritsuro Suzuki, Shigeo Nakamura, Tomohiro Kinoshita

EClinicalMedicine 80 103078 - 103078 2025年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without a timely diagnosis. To explore the safety and efficacy of standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted a multicentre, single-arm, phase 2 trial in untreated IVLBCL patients without CNS involvement at diagnosis (PRIMEUR-IVL). In the primary analysis, the PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) of 76% and 2-year overall survival (OS) of 92% with a low incidence (3%) of secondary CNS involvement (sCNSi). METHODS: We present a prespecified final analysis of the PRIMEUR-IVL study including 5-year PFS, OS and cumulative incidence of sCNSi. Participants were enrolled between June 2011 and July 2016, and the data cutoff date for the final analysis was 16 November 2021. The trial was registered in the UMIN Clinical Trial Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165). FINDINGS: With a median follow-up of 7.1 years (interquartile range 5.6-8.7), 5-year PFS in all 37 eligible patients was 68% (95% confidence interval [CI] 50%-80%) and OS was 78% (95% CI 61%-89%). No additional sCNSi was observed after the primary analysis. Severe adverse events after the primary analysis were grade 4 neutropenia (n = 1) and grade 4 myelodysplastic syndrome that did not require specific treatment (n = 1). Eight deaths occurred during the observation period after enrolment, due to primary disease (n = 6), sepsis (n = 1) and unknown sudden death (n = 1). INTERPRETATION: Long-term follow-up data demonstrated durable response for PFS and OS, and low cumulative incidence of sCNSi, indicating the efficacy of standard chemotherapy combined with CNS-directed therapy for untreated IVLBCL patients. FUNDING: This study received financial support from the Japan Agency for Medical Research and Development, Center for Supporting Hematology-Oncology Studies, and National Cancer Center.

DOI： 10.1016/j.eclinm.2025.103078

PubMed

researchmap

抗PD-1抗体投与と同種造血幹細胞移植を実施したCAR-T療法後治療抵抗性PMBLの1例

諏訪部達也, 古山悠里, 柴崎康彦, 武田ルイ, 米沢穂高, 片桐隆幸, 布施香子, 増子正義, 棟方理, 大島孝一, 曽根博仁, 瀧澤淳

臨床血液 65 ( 11 ) 1420 - 1420 2024年11月

　前のページ - 次のページ　

<瀧澤 淳>

論文 - 瀧澤 淳

<瀧澤　淳>

論文 - 瀧澤　淳